scholarly journals Propolypeptide of von Willebrand factor serves as a substrate for factor XIIIa and is cross-linked to laminin

1993 ◽  
Vol 268 (17) ◽  
pp. 12311-12316
Author(s):  
T. Usui ◽  
J. Takagi ◽  
Y. Saito
Blood ◽  
1986 ◽  
Vol 68 (1) ◽  
pp. 95-101 ◽  
Author(s):  
M Hada ◽  
M Kaminski ◽  
P Bockenstedt ◽  
J McDonagh

Abstract Factor XIIIa crosslinks a limited number of substrates via epsilon(gamma-glutamyl)-lysyl bond formation. It crosslinks fibrin to itself, alpha 2-plasmin inhibitor and fibronectin to fibrin, and fibronectin to collagen. Results presented here show that plasma von Willebrand factor (vWF) is a substrate for factor XIIIa and can be crosslinked to fibrin during gel formation. vWF-fibrin crosslinking was studied in purified systems and in plasma with 125I-vWF and 131I- fibrinogen. vWF incorporation into fibrin increased with time or increasing factor XIIIa. After electrophoresis of dissolved clots, distribution of 125I and 131I was measured and showed that vWF was crosslinked to the alpha chain of fibrin and entered the high-mol-wt alpha polymer. vWF-fibrin crosslinking decreased the initial rate of alpha polymer formation. Crosslinking of vWF polymer to itself could not be demonstrated under physiologic conditions but occurred if vWF was reduced first. Factor XIIIa catalyzed incorporation of putrescine into both monomeric and polymeric vWF. Altogether, these studies indicate that factor XIIIa can readily form covalent bonds between glutamine in vWF and lysine in fibrin alpha chains. This reaction occurs readily in vitro when plasma clotting is slow and may occur in vivo under similar conditions.


1995 ◽  
Vol 232 (3) ◽  
pp. 773-777 ◽  
Author(s):  
Junichi Takagi ◽  
Toshihiro Aoyama ◽  
Shoko Ueki ◽  
Hirotsugu Ohba ◽  
Yuji Saito ◽  
...  

2008 ◽  
Vol 232 (3) ◽  
pp. 773-777
Author(s):  
Junichi Takagi ◽  
Toshihiro Aoyama ◽  
Shoko Ueki ◽  
Hirotsugu Ohba ◽  
Yuji Saito ◽  
...  

1987 ◽  
Author(s):  
J A Ribes ◽  
D D Wagner ◽  
C W Francis

von Willebrand factor (vWf) is synthesized in endothelial cells and stored in specialized organelles, the Weibel-Palade bodies. We have examined the role of fibrin as a potential physiological secretagogue of vWf from Weibel-Palade bodies using indirect immunofluorescence staining of endothelial cells to detect release. Addition of fibrinogen to endothelial cell cultures resulted in the formation of a clot, and this was temporally associated with vWf release. Addition to endothelial cells of preformed fibrin prepared by clotting fibrinogen with thrombin also stimulated release of vWf within 10 minutes. Hirudin inhibition or heat denaturation of clot-bound thrombin abolished most of the thrombin activity but did not diminish release. The role of fibrinopeptide A and B (FPA, FPB) cleavage in stimulating release was examined using reptilase or the venom from A. contortrix to selectively remove FPA or FPB. Release was stimulated by fibrin from which FPB had been cleaved by either thrombin or A. contortrix, while desAA fibrin prepared with Reptilase was an ineffective stimulus. The formation of a stimulatory fibrin clot with the contortrix enzyme, which does not cause release by itself, demonstrates that fibrin stimulation was completely independent of thrombin activity. The capacity to stimulate release was found to be independent of factor XIIIa crosslinking with both crosslinked and noncrosslinked FPB cleaved fibrins demonstrating stimulation. We conclude that fibrin stimulates rapid release of vWf from endothelial cells independent of thrombin activity and may function as a physiologic secretagogue. Furthermore, the stimulating capacity is dependant on cleavage of FPB suggesting that release is mediated by an active site near the N-terminal of the 3 chain or is dependent on a fibrin structure resulting from FPB cleavage.


Blood ◽  
1986 ◽  
Vol 68 (1) ◽  
pp. 95-101 ◽  
Author(s):  
M Hada ◽  
M Kaminski ◽  
P Bockenstedt ◽  
J McDonagh

Factor XIIIa crosslinks a limited number of substrates via epsilon(gamma-glutamyl)-lysyl bond formation. It crosslinks fibrin to itself, alpha 2-plasmin inhibitor and fibronectin to fibrin, and fibronectin to collagen. Results presented here show that plasma von Willebrand factor (vWF) is a substrate for factor XIIIa and can be crosslinked to fibrin during gel formation. vWF-fibrin crosslinking was studied in purified systems and in plasma with 125I-vWF and 131I- fibrinogen. vWF incorporation into fibrin increased with time or increasing factor XIIIa. After electrophoresis of dissolved clots, distribution of 125I and 131I was measured and showed that vWF was crosslinked to the alpha chain of fibrin and entered the high-mol-wt alpha polymer. vWF-fibrin crosslinking decreased the initial rate of alpha polymer formation. Crosslinking of vWF polymer to itself could not be demonstrated under physiologic conditions but occurred if vWF was reduced first. Factor XIIIa catalyzed incorporation of putrescine into both monomeric and polymeric vWF. Altogether, these studies indicate that factor XIIIa can readily form covalent bonds between glutamine in vWF and lysine in fibrin alpha chains. This reaction occurs readily in vitro when plasma clotting is slow and may occur in vivo under similar conditions.


Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 101-101
Author(s):  
Adam Miszta ◽  
Leonie Pelkmans ◽  
Theo Lindhout ◽  
Philip De Groot ◽  
Coenraad Hemker ◽  
...  

Abstract Attachment of platelets from the circulation onto a growing thrombus is a process involving multiple platelet receptors, endothelial matrix components and coagulation factors. It has been indicated that VWF crosslinks to polymerizing fibrin. Bound VWF further recruits and activates platelets via interactions with the platelet receptor complex glycoprotein Ib (GPIb). The aim of our study was to investigate the mechanism of VWF incorporation into a fibrin network and thereby characterize the role of VWF in arterial thrombus growth. We monitored the interactions of von Willebrand factor with fibrin(ogen) using different techniques and enzymes in purified test system at high shear stress. Applying surface techniques, ellipsometry and surface plasmon resonance, we real-time observed that VWF does not bind to either a fibrinogen monolayer or to a polymerized fibrin layer formed on the solid surface. However, we found proof for binding of VWF to a fibrin monomer layer during the process of fibrinogen-to-fibrin conversion in the presence of thrombin. Using either Arvin (cleaves FpA but not FpB) or protease III from snake venom Crotalus atrox (cleaves 42 amino acids, where FpB is located) we were able to show that VWF interacts with fibrin monomers. Furthermore, using transmittance measurements we observed that in the presence of VWF the density of the fibrin clot increases suggesting that VWF incorporates into fibrin network in solution. These findings indicate that incorporation of VWF into a fibrin network occurs via the E domain of fibrinogen where FpA and/or FpB were situated. Using a domain deletion mutant deltaC1C2-VWF we demonstrated the involvement of the C1C2 domain of VWF in the binding to fibrin monomers. Our results did not show any interaction of deltaC1C2-VWF with fibrin monolayer in the presence of thrombin. Application of the inhibitor K9-DON against factor XIIIa in the presence of calcium and thrombin slightly decreased the amount of VWF adsorbed on fibrin monolayer but not completely abolished it, illustrating that cross linking via factor XIII is not essential for this phenomenon and suggesting the identification of a second mechanism through which VWF multimers incorporate into a fibrin network. Additionally, under high shear conditions, we were able to show that platelets adhere to fibrin only if VWF had been incorporated. Addition of a GPIb blocking antibody almost completely abolished the adhesion of platelets to the fibrin monomers surface with bound VWF. These data provided evidence that the binding of platelets to a fibrin monomer layer under high shear rate is completely dependent on the VWF-GPIb interaction. All experiments were performed in the presence of abciximab suggesting that the GPIIb/IIIa receptor is not involved in this binding. In conclusion, our experiments show that the C1C2 domain of VWF and the E domain of fibrin monomers are involved in the incorporation of VWF during the polymerization of fibrin and that this incorporation fosters binding and activation of platelets. Fibrin thus is not an inert end product but partakes in further thrombus growth. Our findings help to elucidate the mechanism of thrombus growth and platelet adhesion under conditions of arterial shear rate. Additionally it may help to explain the observed phenotype in types I and III of von Willebrand Disease and the Bernard-Soulier Syndrome. Low amount of (functional) VWF or deficiency in GPIb-IX-V, here lead to disruption in thrombus formation and wound healing. Disclosures No relevant conflicts of interest to declare.


Sign in / Sign up

Export Citation Format

Share Document